Induction of TSH-Receptor Antibodies in Patients with Toxic Multinodular Goitre by Radioiodine Treatment

Abstract

Previous studies have indicated pre-existing subclinical Graves' disease (GD) in many patients with the scintigraphic diagnosis of disseminated thyroid autonomy (DISA) or toxic multinodular goitre (TMG) type A. After radioiodine (RAI) treatment, an increase or the induction of TSH-receptor antibodies (TRAbs) in patients with GD or TMG has been repeatedly reported.

In the present study, we investigated whether RAI could induce TRAbs in patients with TMG in whom pre-existing GD was excluded with highly sensitive TBII and TSAB assays. Therefore, TRAbs, anti-thyroperoxidase antibodies (anti-TPO-Abs) and anti-thyroglobulin antibodies (anti-TG-Abs) were determined in 43 consecutive patients at the nuclear medicine outpatient clinic with the scintigraphic diagnosis of toxic adenoma (TA; n = 20) or TMG type A (n = 11) or type B (n = 12) before and after RAI treatment. After RAI therapy, we detected TRAbs in 36 % (4 of 11) of patients with TMG type A only, whereas TRAbs were not detectable in patients with TMG type B or in patients with TA. Furthermore, 3 of the 4 patients with detectable TRAbs after RAI showed positive anti-TPO-Abs before RAI therapy. These findings provide further evidence for pre-existing GD in patients with TMG type A or DISA as previously suggested. Therefore, patients with TMG type A and high anti-TPO-Abs seem to be at increased risk of developing TRAbs or side-effects such as relapse of hyperthyroidism or thyroid associated ophthalmopathy. These patients therefore require more frequent evaluation after RAI treatment.

Key words

Radioiodine Treatment - TSH-Receptor Antibodies - Toxic Adenoma - Toxic Multinodular Goitre - Graves' Disease

References

• 1 DeGroot L J. Radioiodine and the immune system.  Thyroid. 1997;  7 259-264
• 2 Nygaard B, Faber J, Veje A, Hegedus L, Hansen J M. Appearance of Graves'-like disease after radioiodine therapy for toxic as well as non-toxic multinodular goitre.  Clin Endocrinol (Oxf). 1995;  43 129-130
• 3 Nygaard B, Knudsen J H, Hegedus L, Scient A V, Hansen J E. Thyrotropin receptor antibodies and Graves' disease, a side-effect of 131I treatment in patients with nontoxic goiter.  J Clin Endocrinol Metab. 1997;  82 2926-2930
• 4 Nygaard B, Faber J, Veje A, Hegedus L, Hansen J M. Transition of nodular toxic goiter to autoimmune hyperthyroidism triggered by 131I therapy.  Thyroid. 1999;  9 477-481
• 5 Nygaard B, Metcalfe R A, Phipps J, Weetman A P, Hegedus L. Graves' disease and thyroid associated ophthalmopathy triggered by 131I treatment of non-toxic goiter.  J Endocrinol Invest. 1999;  22 481-485
• 6 Boddenberg B, Voth E, Schicha H. (Immunogenic hyperthyroidism following radioiodine ablation of a focal autonomy).  Nuklearmedizin. 1993;  32 18-22
• 7 Chiovato L, Santini F, Vitti P, Bendinelli G, Pinchera A. Appearance of thyroid stimulating antibody and Graves' disease after radioiodine therapy for toxic nodular goitre (see comments).  Clin Endocrinol (Oxf). 1994;  40 803-806
• 8 Smyth P P, Neylan D, McMullan N M, Smith D F, McKenna T J. Sequential presentation of a case of hyperthyroidism with autonomously functioning nodules and Graves' disease in the presence of IgG thyroid stimulators.  Acta Endocrinol (Copenh). 1988;  118 474-478
• 9 Wallaschofski H, Orda C, Georgi P, Paschke R. Distinction between autoimmune and nonautoimmune hyperthyroidism by determination of TSH-receptor antibodies in patients with the initial diagnosis of toxic multinodular goitre.  Horm Metab Res. 2001;  33 504-507
• 10 Kraiem Z, Glaser B, Yigla M, Pauker J, Sadeh O, Sheinfeld M. Toxic multinodular goiter: a variant of autoimmune hyperthyroidism.  J Clin Endocrinol Metab. 1987;  65 659-664
• 11 Meller J, Jauho A, Hufner M, Gratz S, Becker W. Disseminated thyroid autonomy or Graves' disease: reevaluation by a second generation TSH receptor antibody assay.  Thyroid Dec. 2000;  10 1073-1079
• 12 Wallaschofski H, Kaczmarek M, Miehle K, Hentschel B, Paschke R. Differences between thyrotropin receptor antibody bioactivity and inhibition of 125I-bovine thyrotropin binding.  Thyroid. 2000;  10 897-907
• 13 Weetman A P. Graves' disease by any other name?.  Thyroid. 2000;  10 1071-1072
• 14 Michelangeli V, Poon C, Taft J, Newnham H, Topliss D, Colman P. The prognostic value of thyrotropin receptor antibody measurement in the early stages of treatment of Graves' disease with antithyroid drugs.  Thyroid. 1998;  8 119-124
• 15 Schleusener H, Schwander J, Fischer C, Holle R, Holl G, Badenhoop K, Hensen J, Finke R, Bogner U, Mayr W R. Prospective multicentre study on the prediction of relapse after antithyroid drug treatment in patients with Graves' disease [published erratum appears in Acta Endocrinol (Copenh) 1989 Aug; 121 (2): 304].  Acta Endocrinol (Copenh). 1989;  120 689-701
• 16 Vitti P, Rago T, Chiovato L, Pallini S, Santini F, Fiore E, Rocchi R, Martino E, Pinchera A. Clinical features of patients with Graves' disease undergoing remission after antithyroid drug treatment.  Thyroid. 1997;  7 369-375
• 17 Weetman A P. Medical Progress: Graves' Disease.  N Engl J Med. 2000;  343 1236-1248
• 18 Wallaschofski H, Paschke R. Detection of thyroid stimulating (TSAB)- and thyrotropin stimulation blocking (TSBAB)-antibodies with CHO cell lines expressing different TSH-receptor numbers.  Clin Endocrinol (Oxf). 1999;  50 365-372
• 19 Chazenbalk G D, Pichurin P, McLachlan S M, Rapoport B. A direct binding assay for thyrotropin receptor autoantibodies.  Thyroid. 1999;  9 1057-1061
• 20 Sanders J, Oda Y, Roberts S, Kiddie A, Richards T, Bolton J, McGrath V, Walters S, Jaskolski D, Furmaniak J, Smith B R. The interaction of TSH receptor autoantibodies with 125I-labelled TSH receptor.  J Clin Endocrinol Metab. 1999;  84 3797-3802
• 21 Yamano Y, Takamatsu J, Sakane S, Hirai K, Kuma K, Ohsawa N. Differences between changes in serum thyrotropin-binding inhibitory antibodies and thyroid-stimulating antibodies in the course of antithyroid drug therapy for Graves' disease.  Thyroid. 1999;  9 769-773
• 22 Ludgate M. Animal models of Graves' disease.  European Journal of Endocrinology. 2000;  142 1-8